Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy

NCT02012218 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

61

Enrollment

INDUSTRY

Sponsor class

Conditions

Major Depressive Disorder (MDD)

Interventions

DRUG: ADT
DRUG: Brexpiprazole

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.

Collaborators

[object Object]